Retraction notice to "Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective" [Biomedicine & Pharmacotherapy 157 (2023) 113991] - 21/05/26
Doi : 10.1016/j.biopha.2026.119500
Yufang Liu a, b, Han Yang a, b, Jie Xiong a, b, Juanjuan Zhao a, b, Mengmeng Guo a, b, Jing Chen a, b, Xu Zhao a, b, Chao Chen a, b, Zhixu He c, Ya Zhou a, ⁎, Lin Xu a, b, ⁎
a Special Key Laboratory of Gene Detection &Therapy of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou 563000, China
b Department of Immunology, Zunyi Medical University, Zunyi, Guizhou 563000, China
c Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine of Zunyi Medical University, Zunyi, Guizhou 563000, China
⁎ Corresponding authors.
Le texte complet de cet article est disponible en PDF.
© 2026
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 199
Article 119500- juin 2026 Retour au numéro
Article précédent
- Retraction notice to "Synthesis and antidepressant-like effects of new 5-epi-incensole and 5-epi- incensole acetate in chronic unpredictable mild stress model of depression; behavioural and biochemical correlates" [Biomedicine & Pharmacotherapy 156 (2022) 113960]
- Satya Kumar Avula, Ajmal Khan, Sobia Ahsan Halim, Najeeb Ur Rehman, Nasiara Karim, Imran Khan, Rene Csuk, Biswanath Das, Ahmed Al-Harrasi
- Retraction notice to "Attenuation of dermal wounds via downregulating oxidative stress and inflammatory markers by protocatechuic acid rich n-butanol fraction of Trianthema portulacastrum Linn. in wistar albino rats" [Biomedicine & Pharmacotherapy 96 (2017) 86-97]
- Ekta Yadav, Deepika Singh, Pankajkumar Yadav, Amita Verma
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?